(Reuters) - But sales of its flagship Lexapro anti-depressant failed to climb as much as some analysts expected, and the company did not raise its full-year forecast despite the better-than-expected quarterly performance.
Forest shares fell as much as 2.9 percent in morning trade but recovered some of that ground by early afternoon.
Read more at Reuters.com Business News
Forest shares fell as much as 2.9 percent in morning trade but recovered some of that ground by early afternoon.
Read more at Reuters.com Business News
No comments:
Post a Comment